Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



AstraZeneca Steady After Patent Setback

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

LONDON -- AstraZeneca's (LSE: AZN  ) (NYSE: AZN  ) share price remains resiliently steady following news that the Federal Court of Australia has found three patents protecting Crestor -- AstraZeneca's rosuvastatin medication, for the treatment of high cholesterol -- to be invalid.

The company was quick to point out that the judgment is limited to Australia and has no impact on patents held elsewhere in the world. It also stated that it doesn't materially affect AstraZeneca's financial guidance for 2013.

Sales of Crestor in Australia during 2012 totaled about $350 million, and the patents were all due to run until at least 2020, so the company could potentially lose a large amount of revenue there if generic alternatives were available. The company said that it will be exploring all legal avenues open to it, which could include appealing the court's decision, or seeking to maintain existing injunctions.

The patent blow comes on the back of poor trading figures from the company at the end of January, when it announced that annual sales had slipped 17%, largely due to the loss of patent protection and exclusivity on some of its best-selling treatments, including Seroquel IR (a treatment for schizophrenia and bipolar disorder) and Nexium (a heartburn remedy).

And the problems seem set to continue to for some time, with the company already anticipating a mid-to-high single-digit percentage drop in revenue for 2013, with core earnings per share set to decline even more significantly, owing to higher core operating costs.

Despite all this, AstraZeneca remains a favorite of investment guru Neil Woodford, who has a remarkable track record of picking winners.

If you want to know more about why Woodford likes AstraZeneca, and some of the dividend-paying blue chips he currently favors, get hold of the FREE Motley Fool report, "8 Shares Held By Britain's Super Investor" now!

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2293156, ~/Articles/ArticleHandler.aspx, 10/28/2016 10:43:54 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,205.15 35.47 0.20%
S&P 500 2,137.58 4.54 0.21%
NASD 5,215.96 -0.01 0.00%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/28/2016 10:28 AM
AZN $4583.00 Down -31.50 -0.68%
AstraZeneca CAPS Rating: No stars
AZN $28.34 Down -0.20 -0.70%
AstraZeneca CAPS Rating: ****